Consistent with the latter, the recent study by Garcia-Recio et al. demonstrated tumor growth inhibition in a HER2-negative HER2E PDX-model treated with an FGFR4 inhibitor, but also molecular subtype switching in cancer cells due to FGFR4 inhibition59. The gene discussed is ERBB2; the disease is cancer.